Innoviva Receivables 2010-2024 | INVA

Innoviva receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
Innoviva Annual Receivables
(Millions of US $)
2023 $84
2022 $64
2021 $111
2020 $94
2019 $79
2018 $83
2017 $71
2016 $47
2015 $26
2014 $11
2013 $3
2012 $1
2011 $0
2010 $0
2009 $0
Innoviva Quarterly Receivables
(Millions of US $)
2024-09-30 $91
2024-06-30 $94
2024-03-31 $76
2023-12-31 $84
2023-09-30 $68
2023-06-30 $81
2023-03-31 $76
2022-12-31 $64
2022-09-30 $72
2022-06-30 $112
2022-03-31 $94
2021-12-31 $111
2021-09-30 $101
2021-06-30 $104
2021-03-31 $89
2020-12-31 $94
2020-09-30 $92
2020-06-30
2020-03-31 $82
2019-12-31 $79
2019-09-30 $69
2019-06-30 $68
2019-03-31 $59
2018-12-31 $83
2018-09-30 $65
2018-06-30 $71
2018-03-31 $56
2017-12-31 $71
2017-09-30 $52
2017-06-30 $62
2017-03-31 $44
2016-12-31 $47
2016-09-30 $37
2016-06-30 $36
2016-03-31 $28
2015-12-31 $26
2015-09-30 $17
2015-06-30 $14
2015-03-31 $10
2014-12-31 $11
2014-09-30 $4
2014-06-30 $3
2014-03-31 $1
2013-12-31 $3
2013-09-30 $3
2013-06-30 $2
2013-03-31 $2
2012-12-31 $1
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $0
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.263B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80